Moteur de recherche d’entreprises européennes
Financement de l’UE (9 983 029 €) : Profilage immunitaire pour guider les interventions dirigées par l’hôte pour guérir les infections par le VHB Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Profilage immunitaire pour guider les interventions dirigées par l’hôte pour guérir les infections par le VHB
The objective of the project is to develop novel curative concepts for chronic hepatitis B (CHB). Specific aims will be to: 1) improve the rate of functional cure of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine; ii) characterize immune and viral biomarker signatures for patient stratification and treatment response monitoring; iii) integrate biological and clinical data to model the best combination treatment for future trials; iv) model the effectiveness of novel curative therapies with respect to disease spectrum, patient heterogeneity, and constraints of National Health Systems. The project organization will combine: i) a Proof of Concept clinical trial of a combination of 2 novel compounds stimulating innate immunity; ii) a preclinical immune therapy platform in humanized mice combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses; iii) extensive virologic and immune profiling to identify correlates of cure in patients, iv) the integration of large biological and clinical datasets, v) a cost-effectiveness modelling of new therapeutic interventions, vi) project management, vii) results exploitation and dissemination. The proposal responds to the work program by: i) including the evaluation of emerging concepts in drug and vaccine development to discover a curative strategy for CHB, a major public health concern for Europe, ii) capitalizing on knowledge of host-pathogen interactions to develop novel immune-based therapies, iii) considering age, gender and viral genetic variations, iv) comprising a clinical trial and a pre-clinical platform for the discovery of novel immune interventions, and selection of relevant biomarkers for validation in established clinical cohorts, v) addressing conditions for effective uptake of the new curative interventions by National Health Systems.
| 0,00 € | |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | 690 049 € |
| CHU Hopitaux de Bordeaux | 0,00 € |
| 30 379 € | |
| European Liver Patients Association | 175 000 € |
| Fondazione Irccs CA' Granda - Ospedale Maggiore Policlinico | 198 538 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 211 444 € |
| Gilead Sciences Inc. | 0,00 € |
| Hospices Civils de Lyon | 200 000 € |
| Inserm Transfert SA | 300 000 € |
| Institut National de la Sante et de la Recherche Medicale | 4 324 129 € |
| Institut Pasteur | 1 593 800 € |
| Karolinska Institutet | 299 550 € |
| UNIVERSITAETSKLINIKUM FREIBURG | 863 401 € |
| Universita Degli Studi DI Parma | 1 096 740 € |
| Universite Grenoble Alpes | 0,00 € |
https://cordis.europa.eu/project/id/847939
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Azienda Ospedaliero-Universitaria DI Parma - Financement de l’UE (9 983 029 €) : Profilage immunitaire pour guider les interventions dirigées par l’hôte pour guérir les infections par le VHB"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
